Matthew Boyd
Fortune : 12 975 $ au 30/06/2026
Fortune : 12 975 $ au 30/06/2026
Matthew Boyd is Chief Regulatory Officer at enGene Therapeutics, Inc. starting in 2025.
Formerly, Mr. Boyd was Vice President-Regulatory Affairs at Albireo Pharma, Inc. and Head-Regulatory Affairs & Quality Assurance at Zambon Usa Ltd. Education includes an undergraduate degree from Philadelphia College of Pharmacy and an MBA from Kelley School of Business.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ENGENE THERAPEUTICS INC. 0,01 % | 16/06/2026 | 7 500 ( 0,01 % ) | 12 975 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ENGENE THERAPEUTICS INC. | Conseiller Juridique Général | 01/09/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| ALBIREO PHARMA, INC. | Conseiller Juridique Général | - |
Zambon Usa Ltd.
Zambon Usa Ltd. Pharmaceuticals: OtherHealth Technology Zambon Usa Ltd. is an American company. The company is located in the US. | Conseiller Juridique Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Kelley School of Business
Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Philadelphia College of Pharmacy
Philadelphia College of Pharmacy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
Zambon Usa Ltd.
Zambon Usa Ltd. Pharmaceuticals: OtherHealth Technology Zambon Usa Ltd. is an American company. The company is located in the US. | Health Technology |
enGene Holdings, Inc.
enGene Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops, manufactures and sells non-viral genetic medicines | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national